One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
From Race-Based to Equity-Informed Antihypertensive Medication Selection: Rationale for the 2025 AHA/ACC Guideline Change.
doi : 10.1161/CIRCULATIONAHA.125.077650
Volume 153(3) pgs. 137-212,e14-e20 January 20, 2026
Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial.
Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering.
Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome.
ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.
Selective mRNA Translation: A New Player in Ferroptosis After Myocardial Infarction.
Histone Lactylation-Mediated Metabolic Remodeling in Vascular Smooth Muscle Cells Aggravates Aortic Aneurysm and Dissection by Promoting Lactate Accumulation.
Effects of Real-Time Notification of AI-Detected Incidental Coronary Artery Calcium on Statin Prescription: The NOTIFY-PICTURE Trial.
Letter by Pyrpyris et al Regarding Article, "Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy".
Letter by Sun Regarding Article, "Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy".
Response by Maeng et al to Letters Regarding Article, "Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy".
Correction to: Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes.
Correction to: Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.
